• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新型冠状病毒感染与心血管疾病:COVID-19 心脏。

SARS-CoV-2 Infection and Cardiovascular Disease: COVID-19 Heart.

机构信息

Sarver Heart Center, University of Arizona, Tucson, AZ, USA.

Sarver Heart Center, University of Arizona, Tucson, AZ, USA.

出版信息

Heart Lung Circ. 2020 Jul;29(7):973-987. doi: 10.1016/j.hlc.2020.05.101. Epub 2020 Jun 5.

DOI:10.1016/j.hlc.2020.05.101
PMID:32601020
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7274628/
Abstract

Coronavirus disease (COVID-19) is a serious illness caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The symptoms of the disease range from asymptomatic to mild respiratory symptoms and even potentially life-threatening cardiovascular and pulmonary complications. Cardiac complications include acute myocardial injury, arrhythmias, cardiogenic shock and even sudden death. Furthermore, drug interactions with COVID-19 therapies may place the patient at risk for arrhythmias, cardiomyopathy and sudden death. In this review, we summarise the cardiac manifestations of COVID-19 infection and propose a simplified algorithm for patient management during the COVID-19 pandemic.

摘要

冠状病毒病(COVID-19)是由严重急性呼吸系统综合征冠状病毒 2(SARS-CoV-2)引起的严重疾病。该疾病的症状范围从无症状到轻度呼吸道症状,甚至可能导致危及生命的心血管和肺部并发症。心脏并发症包括急性心肌损伤、心律失常、心源性休克甚至猝死。此外,COVID-19 疗法的药物相互作用可能使患者面临心律失常、心肌病和猝死的风险。在这篇综述中,我们总结了 COVID-19 感染的心脏表现,并提出了一种简化的算法,用于 COVID-19 大流行期间的患者管理。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c561/7274628/ac182b9c391b/gr3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c561/7274628/d91500a4d015/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c561/7274628/e727facddf60/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c561/7274628/ac182b9c391b/gr3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c561/7274628/d91500a4d015/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c561/7274628/e727facddf60/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c561/7274628/ac182b9c391b/gr3_lrg.jpg

相似文献

1
SARS-CoV-2 Infection and Cardiovascular Disease: COVID-19 Heart.新型冠状病毒感染与心血管疾病:COVID-19 心脏。
Heart Lung Circ. 2020 Jul;29(7):973-987. doi: 10.1016/j.hlc.2020.05.101. Epub 2020 Jun 5.
2
COVID-19 and the Heart.新型冠状病毒肺炎与心脏
Circ Res. 2020 May 8;126(10):1443-1455. doi: 10.1161/CIRCRESAHA.120.317055. Epub 2020 Apr 7.
3
A care pathway for the cardiovascular complications of COVID-19: Insights from an institutional response.COVID-19 心血管并发症的护理路径:来自机构应对的见解。
Am Heart J. 2020 Jul;225:3-9. doi: 10.1016/j.ahj.2020.04.024. Epub 2020 May 3.
4
Acute kidney injury in COVID-19: a case-report.新型冠状病毒肺炎相关急性肾损伤:一例病例报告
Int Urol Nephrol. 2020 Nov;52(11):2213-2214. doi: 10.1007/s11255-020-02635-3. Epub 2020 Sep 8.
5
Advances in the relationship between coronavirus infection and cardiovascular diseases.冠状病毒感染与心血管疾病关系的研究进展。
Biomed Pharmacother. 2020 Jul;127:110230. doi: 10.1016/j.biopha.2020.110230. Epub 2020 May 13.
6
Myocarditis in Multisystem Inflammatory Syndrome in Children Associated With Coronavirus Disease 2019.儿童多系统炎症综合征与 2019 年冠状病毒病相关的心肌炎。
Cardiol Rev. 2020 Nov/Dec;28(6):308-311. doi: 10.1097/CRD.0000000000000341.
7
Pathophysiology and treatment strategies for COVID-19.COVID-19 的病理生理学和治疗策略。
J Transl Med. 2020 Sep 15;18(1):353. doi: 10.1186/s12967-020-02520-8.
8
Coronavirus disease 2019 and cardiovascular implications.新型冠状病毒病 2019 与心血管影响。
J Cardiovasc Med (Hagerstown). 2020 Oct;21(10):725-732. doi: 10.2459/JCM.0000000000001068.
9
Current data on the cardiovascular effects of COVID-19.关于新冠病毒病心血管影响的当前数据。
Hellenic J Cardiol. 2020 Jan-Feb;61(1):46-48. doi: 10.1016/j.hjc.2020.04.001. Epub 2020 Apr 18.
10
Feel Better, Work Better: The COVID-19 Perspective.感觉更好,工作更高效:新冠疫情视角
Can J Cardiol. 2020 Jun;36(6):789-791. doi: 10.1016/j.cjca.2020.04.012. Epub 2020 Apr 16.

引用本文的文献

1
Artificial Intelligence in Cardiovascular Health: Insights into Post-COVID Public Health Challenges.心血管健康领域的人工智能:对新冠疫情后公共卫生挑战的洞察
High Blood Press Cardiovasc Prev. 2025 Sep 16. doi: 10.1007/s40292-025-00738-5.
2
Outcomes of percutaneous coronary intervention in COVID-19-positive acute coronary syndrome patients: a retrospective study in Vietnam.新型冠状病毒肺炎阳性急性冠状动脉综合征患者经皮冠状动脉介入治疗的结果:越南的一项回顾性研究
Front Cardiovasc Med. 2025 Jul 10;12:1563415. doi: 10.3389/fcvm.2025.1563415. eCollection 2025.
3
Post-coronavirus Disease 2019 (COVID-19) Cardiovascular Manifestations: A Systematic Review of Long-Term Risks and Outcomes.

本文引用的文献

1
Modelling transmission and control of the COVID-19 pandemic in Australia.模拟澳大利亚 COVID-19 大流行的传播和控制。
Nat Commun. 2020 Nov 11;11(1):5710. doi: 10.1038/s41467-020-19393-6.
2
Remdesivir for the Treatment of Covid-19 - Preliminary Report. Reply.瑞德西韦治疗新冠病毒病-初步报告。回复。
N Engl J Med. 2020 Sep 3;383(10):994. doi: 10.1056/NEJMc2022236. Epub 2020 Jul 10.
3
CSANZ Position Statement on the Evaluation of Patients Presenting With Suspected Acute Coronary Syndromes During the COVID-19 Pandemic.
2019冠状病毒病(COVID-19)的心血管表现:长期风险和结局的系统评价
Cureus. 2025 Apr 27;17(4):e83083. doi: 10.7759/cureus.83083. eCollection 2025 Apr.
4
Characteristics and Outcomes of New-Onset Cardiomyopathy in Hospitalized COVID-19 Patients.住院COVID-19患者新发心肌病的特征与结局
J Clin Med. 2025 May 7;14(9):3258. doi: 10.3390/jcm14093258.
5
The Detection of , and in Non-Atherosclerotic Arteries of Patients with Coronary Artery Disease.冠状动脉疾病患者非动脉粥样硬化动脉中[具体物质]、[具体物质]和[具体物质]的检测
Pathogens. 2024 Oct 25;13(11):927. doi: 10.3390/pathogens13110927.
6
Coronary Computed Tomography Angiography (CTA) Findings in COVID-19.新型冠状病毒肺炎的冠状动脉计算机断层扫描血管造影(CTA)表现
J Cardiovasc Dev Dis. 2024 Oct 14;11(10):325. doi: 10.3390/jcdd11100325.
7
Addressing SARS-CoV-2 viroporins with antiarrhythmic drugs.用抗心律失常药物治疗严重急性呼吸综合征冠状病毒2(SARS-CoV-2)病毒孔蛋白
Europace. 2024 Oct 3;26(10). doi: 10.1093/europace/euae254.
8
The Correlation between Cardiac Magnetic Resonance Findings and Post-COVID-19: The Impact of Myocardial Injury on Quality of Life.心脏磁共振成像结果与新冠后情况的相关性:心肌损伤对生活质量的影响。
Diagnostics (Basel). 2024 Sep 2;14(17):1937. doi: 10.3390/diagnostics14171937.
9
Echocardiographic Assessment of Recovered Patients with Mild COVID-19 Infection: A Case-Control Study.轻度新型冠状病毒肺炎感染康复患者的超声心动图评估:一项病例对照研究
J Cardiovasc Echogr. 2024 Apr-Jun;34(2):72-76. doi: 10.4103/jcecho.jcecho_3_24. Epub 2024 Jun 28.
10
COVID-19 and Cardiac Implications-Still a Mystery in Clinical Practice.新冠病毒肺炎及其心脏影响——临床实践中仍是个谜
Rev Cardiovasc Med. 2023 Apr 24;24(5):125. doi: 10.31083/j.rcm2405125. eCollection 2023 May.
CSANZ 关于在 COVID-19 大流行期间评估疑似急性冠状动脉综合征患者的立场声明。
Heart Lung Circ. 2020 Jul;29(7):e105-e110. doi: 10.1016/j.hlc.2020.05.003. Epub 2020 May 21.
4
Rural and Remote Cardiology During the COVID-19 Pandemic: Cardiac Society of Australia and New Zealand (CSANZ) Consensus Statement.农村和偏远地区心脏病学在 COVID-19 大流行期间:澳大利亚和新西兰心脏病学会(CSANZ)共识声明。
Heart Lung Circ. 2020 Jul;29(7):e88-e93. doi: 10.1016/j.hlc.2020.05.001. Epub 2020 May 7.
5
Optimising Secondary Prevention and Cardiac Rehabilitation for Atherosclerotic Cardiovascular Disease During the COVID-19 Pandemic: A Position Statement From the Cardiac Society of Australia and New Zealand (CSANZ).《澳大利亚和新西兰心脏病学会(CSANZ)在 COVID-19 大流行期间优化动脉粥样硬化性心血管疾病二级预防和心脏康复的立场声明》。
Heart Lung Circ. 2020 Jul;29(7):e99-e104. doi: 10.1016/j.hlc.2020.04.007. Epub 2020 Apr 30.
6
Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans.非裔美国人 COVID-19 患者的肺部和心脏病理学:来自新奥尔良的尸检系列。
Lancet Respir Med. 2020 Jul;8(7):681-686. doi: 10.1016/S2213-2600(20)30243-5. Epub 2020 May 27.
7
CSANZ Imaging Council Position Statement on Echocardiography Services During the COVID-19 Pandemic.CSANZ 成像委员会关于 COVID-19 大流行期间超声心动图服务的立场声明。
Heart Lung Circ. 2020 Jun;29(6):e78-e83. doi: 10.1016/j.hlc.2020.04.003. Epub 2020 May 6.
8
Remdesivir for 5 or 10 Days in Patients with Severe Covid-19.瑞德西韦治疗重症 COVID-19 患者的 5 天与 10 天疗程比较
N Engl J Med. 2020 Nov 5;383(19):1827-1837. doi: 10.1056/NEJMoa2015301. Epub 2020 May 27.
9
Position Statement on the Management of Cardiac Electrophysiology and Cardiac Implantable Electronic Devices in Australia During the COVID-19 Pandemic: A Living Document.COVID-19 大流行期间澳大利亚心脏电生理学和心脏植入式电子设备管理立场声明:一份实时文件。
Heart Lung Circ. 2020 Jun;29(6):e57-e68. doi: 10.1016/j.hlc.2020.04.001. Epub 2020 May 11.
10
Joint HFSA/ACC/AHA Statement Addresses Concerns Re: Using RAAS Antagonists in COVID-19.美国心力衰竭学会/美国心脏病学会/美国心脏协会联合声明回应关于在2019冠状病毒病中使用肾素-血管紧张素-醛固酮系统拮抗剂的担忧。
J Card Fail. 2020 May;26(5):370. doi: 10.1016/j.cardfail.2020.04.013.